BACK

M65® ELISA References

REFERENCES IN CHRONOLOGICAL ORDER

(Updated on March 18, 2010)

2010

Dive C, Smith RA, Garner E, Ward T, George-Smith SS, Campbell F, Greenhalf W, Ghaneh P, Neoptolemos JP. (2010)
Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer.
Br J Cancer 102:577-82.
»Abstract

Kahraman A, Schlattjan M, Kocabayoglu P, Yildiz-Meziletoglu S, Schlensak M, Fingas CD, Wedemeyer I, Marquitan G, Gieseler RK, Baba HA, Gerken G, Canbay A. (2010)
Major histocompatibility complex class I-related chains A and B (MIC A/B): a novel role in nonalcoholic steatohepatitis.
Hepatology 51, 92-102.
»Abstract

2009

Ausch C, Buxhofer-Ausch V, Olszewski U, Schiessel R, Ogris E, Hinterberger W, Hamilton G. (2009)
Circulating Cytokeratin 18 Fragment M65-A Potential Marker of Malignancy in Colorectal Cancer Patients.
J Gastrointest Surg. 2009 Sep 2.
»Abstract

Ausch C, Buxhofer-Ausch V, Olszewski U, Hinterberger W, Ogris E, Schiessel R, Hamilton G. (2009)
Caspase-cleaved cytokeratin 18 fragment (M30) as marker of postoperative residual tumor load in colon cancer patients.
Eur J Surg Oncol. 2009 Nov;35(11):1164-8.
»Abstract

Bantel H, Schulze-Osthoff K. (2009)
Cell death in sepsis: a matter of how, when, and where.
Crit Care. 2009;13(4):173.
»Abstract

Fisher MB, Zhang XQ, McConkey DJ, Benedict WF. (2009)
Measuring soluble forms of extracellular cytokeratin 18 identifies both apoptotic and necrotic mechanisms of cell death produced by adenoviral-mediated interferon alpha: possible use as a surrogate marker.
Cancer Gene Ther. 2009 Feb 6. [Epub ahead of print]
»Abstract

Hou JM, Greystoke A, Lancashire L, Cummings J, Ward T, Board R, Amir E, Hughes S, Krebs M, Hughes A, Ranson M, Lorigan P, Dive C, Blackhall FH. (2009)
Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy.
Am J Pathol. 2009 Aug;175(2):808-16.
»Abstract

Hofer S, Brenner T, Bopp C, Steppan J, Lichtenstern C, Weitz J, Bruckner T, Martin E, Hoffmann U, Weigand MA. (2009)
Cell death serum biomarkers are early predictors for survival in severe septic patients with hepatic dysfunction
Critical Care 2009, 13:R93.
»Abstract and article

Jochum C, Gieseler RK, Gawlista I, Fiedler A, Manka P, Saner FH, Roggendorf M, Gerken G, Canbay A. (2009)
Hepatitis B-associated Acute Liver Failure: Immediate Treatment with Entecavir Inhibits Hepatitis B Virus Replication and Potentially Its Sequelae
Digestion. 2009 Oct 15;80(4):235-240.
»Abstract

Koelink PJ, Lamers CB, Hommes DW, Verspaget HW. (2009)
Circulating cell death products predict clinical outcome of colorectal cancer patients.
BMC Cancer. 2009 Mar 23;9:88.
»Abstract

Koelink PJ, Sier CF, Hommes DW, Lamers CB, Verspaget HW. (2009)
Clinical significance of stromal apoptosis in colorectal cancer.
Br J Cancer. 101:765-73.
»Abstract

Linder S, Alaiya A. (2009)
Serum efficacy biomarkers for oncology.
Biomarkers Med. 2009, Vol. 3, No. 1, Pages 47-54
»Abstract

Ozturk B, Coskun U, Sancak B, Yaman E, Buyukberber S, Benekli M. (2009)
Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors.
Int Immunopharmacol. 2009 Feb 26. [Epub ahead of print]
»Abstract

Scott LC, Evans TR, Cassidy J, Harden S, Paul J, Ullah R, O'Brien V, Brown R. (2009)
Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response.
Br J Cancer. 2009 Aug 4;101(3):410-7.
»Abstract


2008

Beachy SH, Repasky EA. (2008)
Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update.
Cancer Immunol Immunother. 2008 Jun;57(6):759‑75. Epub 2008 Jan 10.
»Abstract

Bechmann LP., Marquitan G, Jochum C, Saner F, Gerken G, Canbay A. (2008)
Apoptosis versus necrosis rate as a predictor in acute liver failure following acetaminophen intoxication compared with acute‑on‑chronic liver failure
Liver International 2008 May;28(5):713‑6
»Abstract

Carpinelli P, Moll J. (2008)
Aurora kinase inhibitors: identification and preclinical validation of their biomarkers.
Expert Opin Ther Targets. 2008 Jan;12(1):69‑80.
»Abstract

Cummings J, Hodgkinson C, Odedra R, Sini P, Heaton SP, Mundt KE, Ward TH,
Wilkinson RW, Growcott J, Hughes A, Dive C. (2008)
Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity.
Mol Cancer Ther. 2008 Mar;7(3):455‑63.
»Abstract

Cummings J, Ward TH, Greystoke A, Ranson M, Dive C. (2008)
Biomarker method validation in anticancer drug development.
Br J Pharmacol. 2008 Feb;153(4):646‑56. Epub 2007 Sep 17.
»Abstract

de Haas EC, di Pietro A, Simpson KL, Meijer C, Suurmeijer AJ, Lancashire LJ, Cummings J, de Jong S, de Vries EG, Dive C, Gietema JA. (2008)
Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug‑sensitive tumor, testicular cancer.
Neoplasia. 2008 Oct;10(10):1041‑8.
»Abstract

Greystoke A, Cummings J, Ward T, Simpson K, Renehan A, Butt F, Moore D, Gietema J, Blackhall F, Ranson M, Hughes A, Dive C. (2008)
Optimisation of circulating biomarkers of cell death for routine clinical use.
Ann Oncol. 2008 Feb 27  [Epub ahead of print]
»Abstract

Krysko DV, Vanden Berghe T, D'Herde K, Vandenabeele P. (2008)
Apoptosis and necrosis: detection, discrimination and phagocytosis.
Methods. 2008 Mar;44(3):205‑21.
»Abstract

Micha D, Cummings J, Shoemaker A, Elmore S, Foster K, Greaves M, Ward T, Rosenberg S, Dive C, Simpson K. (2008)
Circulating biomarkers of cell death after treatment with the BH‑3 mimetic ABT‑737 in a preclinical model of small‑cell lung cancer.
Clin Cancer Res. 2008 Nov 15;14(22):7304‑10.
»Abstract

Simopoulos C, Tsaroucha AK, Asimakopoulos B, Giatromanolaki A, Gavriilidis P, Polychronidis A, Karayiannakis A. (2008)
Total and caspase‑cleaved cytokeratin 18 in chronic cholecystitis: A prospective study.
BMC Gastroenterol. 2008 May 6;8(1):14 [Epub ahead of print]
»Abstract

Volkmann X, Anstaett M, Hadem J, Stiefel P, Bahr MJ, Lehner F, Manns MP, Schulze‑Osthoff K, Bantel H. (2008)
Caspase activation is associated with spontaneous recovery from acute liver failure.
Hepatology. 2008 May;47(5):1624‑33.
»Abstract

Vos MB, Barve S, Joshi-Barve S, Carew JD, Whitington PF, McClain CJ. (2008)
Cytokeratin 18, a marker of cell death, is increased in children with suspected nonalcoholic fatty liver disease.
J Pediatr Gastroenterol Nutr. 2008 Oct;47(4):481-5
»Abstract

Younossi ZM, Jarrar M, Nugent C, Randhawa M, Afendy M, Stepanova M, Rafiq N, Goodman Z, Chandhoke V, Baranova A. (2008)
A Novel Diagnostic Biomarker Panel for Obesity‑related Nonalcoholic Steatohepatitis (NASH).
Obes Surg. 2008 May 24. [Epub ahead of print]
»Abstract

2007

Cummings J, Ranson M, Butt F, Moore D, Dive C. (2007)
Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma.
Cancer Chemother Pharmacol. 2007 Feb 27;
»Abstract

Cummings J, Ward TH, Greystoke A, Ranson M, Dive C. (2007)
Biomarker method validation in anticancer drug development.
Br J Pharmacol. 2007 Sep 17;1‑11
»Abstract

Klenk M, Nakata M, Podbielski A, Skupin B, Schroten H, Kreikemeyer B. (2007)
Streptococcus pyogenes serotype‑dependent and independent changes in infected HEp‑2 epithelial cells.
ISME J. 2007 Dec;1(8):678‑92. Epub 2007 Oct 18.
»Abstract

Linder, S. (2007)
Cytokeratin Markers Come of Age.
Tumour Biol. 2007 Aug 23;28(4):189‑195 
»Abstract

Olofsson MH, Ueno T, Pan Y, Xu R, Cai F, van der Kuip H, Muerdter TE, Sonnenberg M, Aulitzky WE, Schwarz S, Andersson E, Shoshan MC, Havelka AM, Toi M, Linder S. (2007)
Cytokeratin‑18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy.
Clin Cancer Res. 2007 Jun 1;13(11):3198‑206. 
»Abstract

Yilmaz Y, Dolar E, Ulukaya E, Akgoz S, Keskin M, Kiyici M, Aker S, Yilmaztepe A, Gurel S, Gulten M, Nak SG. (2007)
Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis.
World J Gastroenterol. 2007 Feb 14;13(6):837‑44.
»Abstract

2006

Cummings J, Ranson M, Lacasse E, Ganganagari JR, St‑Jean M, Jayson G, Durkin J, Dive C. (2006)
Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X‑linked inhibitor of apoptosis protein XIAP.
Br J Cancer. 2006 Jul 3;95(1):42‑8.
»Abstract

Kramer, G., Schwartz, S., Hägg, M., Mandic Havelka, A. and Linder, S. (2006)
Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles.
Br J Cancer. 2006 Jun 5;94(11):1592‑8.
»Abstract

2005

Erdal, H., Berndtsson, M., Castro, J., Brunk, U., Shoshan, M.C. and Linder, S. (2005)
Induction of lysosomal membrane permeabilization by compounds that activate p53‑independent apoptosis.
Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):192‑7. Epub 2004 Dec 23.
»Abstract

2004

Cummings J, Ward TH, Ranson M, Dive C. (2004)
Apoptosis pathway‑targeted drugs ‑ from the bench to the clinic.
Biochim Biophys Acta. 2004 Dec 10;1705(1):53‑66.
»Abstract

Kramer, G., Erdal, H., Mertens, H., Nap, M., Mauermann, J., Steiner, G., Marberger, M., Bivén, K., Shoshan, M.C. and Linder, S. (2004)
Differentiation between Cell Death Modes using Measurements of Different Soluble Forms of Extracellular Cytokeratin 18.
Cancer Res. 2004 Mar 1;64(5):1751‑6.
»Abstract

Linder S, Havelka AM, Ueno T, Shoshan MC. (2004)
Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker.
Cancer Lett. 2004 Oct 8;214(1):1‑9.
»Abstract